Christopher Randolph, MD
Allergy · Waterbury, CTNPI 1437142551
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $207,769 of the $268,917 with a category attached, or 77.3%. 37 manufacturers reported payments, led by GSK at 32.2% of the total. Reporting peaked in 2019 at $89,375 and has fallen 78.4% since, to $19,299 in 2025.
Across 826 payments — averaging $325.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$87K
- Sanofi$27K
- AstraZeneca$26K
- CSL Behring$22K
- Boehringer Ingelheim$18K
- Optinose US, Inc.$16K
- plus $73K from 31 others
Across 5 payments — averaging $4004.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$12K
- Biocryst Pharmaceuticals, Inc.$8K
- Merck$52
What the payments were for
- Consulting fees$38,20114%
- Speaking & faculty fees$207,76977%
- Travel & lodging$7,0373%
- Food & beverage$15,5746%
- Education$3360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 171 | $86,503 |
| Sanofi | 55 | $27,306 |
| AstraZeneca | 76 | $25,900 |
| CSL Behring | 54 | $22,255 |
| Boehringer Ingelheim | 34 | $18,143 |
| Optinose US, Inc. | 33 | $15,729 |
| Grifols USA, LLC | 26 | $15,638 |
| Regeneron Healthcare Solutions, Inc. | 77 | $15,551 |
| Amgen(2 entities) | 46 | $10,677 |
| Pfizer | 39 | $9,294 |
| Shire North American Group Inc | 6 | $6,220 |
| Teva Pharmaceuticals USA, Inc. | 3 | $4,202 |
| Pharming Healthcare, Inc. | 18 | $3,324 |
| Biocryst US Sales Co., LLC | 64 | $3,203 |
| Cycle Pharmaceuticals Inc | 4 | $1,440 |
| Eyevance Pharmaceuticals LLC | 2 | $1,100 |
| Novartis | 27 | $557 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $448 |
| Genentech USA, Inc. | 17 | $339 |
| AbbVie(2 entities) | 18 | $323 |
| Kaleo, Inc. | 6 | $111 |
| Alk-abello, Inc | 6 | $108 |
| Sanofi-aventis U.S. LLC | 1 | $77 |
| Merck | 3 | $70 |
| LEO Pharma Inc. | 3 | $54 |
| Aimmune Therapeutics, Inc. | 3 | $51 |
| Stryker | 1 | $49 |
| Octapharma USA, Inc. | 2 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $31 |
| Ionis Pharmaceuticals, Inc. | 1 | $26 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Incyte Corporation | 1 | $19 |
| Circassia Inc. | 1 | $18 |
| Biocryst Pharmaceuticals, Inc. | 1 | $16 |
| Kedrion Biopharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 102 | $368,401 |
| Dupixent PenDupilumab | 16 | $95,342 |
| NucalaMepolizumab | 12 | $43,877 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $43,316 |
| Spiriva RespimatTiotropium Bromide | 40 | $25,029 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $13,376 |
| AirsupraAlbuterol Sulfate/Budesonide | 19 | $8,839 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $6,774 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $5,765 |
| Cyclosporine | 16 | $5,478 |
| DuleraMometasone/Formoterol | 16 | $4,936 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 27 | $3,381 |
| Epinephrine | 21 | $2,367 |
| Azelastine Hcl | 20 | $880 |
| Montelukast Sodium | 45 | $701 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta | $86,503 | $100,56892 claims |
| Boehringer IngelheimSpiriva Respimat | $18,143 | $25,02940 claims |
| AstraZenecaAirsupra, Symbicort | $25,900 | $15,61332 claims |
| MerckDulera | $70 | $4,93616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Connecticuton file to place this against a meaningful peer group, so we don't.
Other allergy in Waterbury
- Lawrence ScheerWaterbury$855
- Doron BerWaterford$14K
- Cristina VoDanbury$4K
- Pamela KwittkenMilford$3K
- Mitchell LesterNorwalk$2K
- Jeffrey MillerTorrington$822
- Hillary Hernandez-TrujilloHartford$501
- Marshall GrodofskyWest Hartford$179
- Michael KrallHartford$142
- Kevin HuntHamden$37
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.